At one month, ticagrelor was not superior to twice-daily clopidogrel in reducing major adverse cardiovascular events (MACEs) ...
Jacksonville, FL - Data from a pharmacodynamic study suggests that acute coronary syndrome (ACS) patients can be safely switched from maintenance clopidogrel (Plavix, Bristol-Myers ...
CURE was one of four large clinical trials that provide a body of evidence that supports the use of dual antiplatelet therapy in patients with acute coronary syndromes and in those undergoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback